Historical trends in survival of hospitalized heart failure patients: 2000 versus 1995.
Historical trends in survival of hospitalized heart failure patients: 2000 versus 1995.
复制标题
DOI：
10.1186/1471-2261-7-2
复制
发表时间：
2007-01-16
影响因子：
2.1
通讯作者：
Lee S
中科院分区：
文献类型：
--
作者：
Shahar E;Lee S
基于人群的充血性心力衰竭（CHF）患者生存的长期趋势是该综合征负担的公共卫生研究的核心。在 22 Minneapolis-St. 22 中发现了 1995 年或 2000 年具有 CHF 出院代码的 35-79 岁患者。保罗医院。提取了记录样本（1995 条记录的 50%；2000 条记录的 38%）。 1995 年和 2000 年共有 2,257 名患者和 1,825 名患者被确定曾因 CHF 住院治疗。对每位患者进行一年的随访以确定其生命状态。 2000 名患者队列的两个性别组的风险状况均比 1995 队列的风险状况稍差，但年龄和左心室射血分数的分布相似。 2000 年入院一年内，28% 的男性患者和 27% 的女性患者死亡，而 1995 年这一数字分别为 36% 和 27%。在各种 Cox 回归模型中，男性的平均年份效应（2000 年与 1995 年相比）约为 0.75，女性为 0.95 至 1.00。使用血管紧张素转换酶抑制剂和β受体阻滞剂与随后一年的死亡风险显着降低有关。 20 世纪 90 年代下半叶，因 CHF 住院的男性的生存率有所改善。女性的趋势非常弱，几乎没有变化。在男性和女性的这些观察数据中，血管紧张素转换酶抑制剂和β受体阻滞剂的益处显而易见。
Population-based secular trends in survival of patients with congestive heart failure (CHF) are central to public health research on the burden of the syndrome. Patients 35–79 years old with a CHF discharge code in 1995 or 2000 were identified in 22 Minneapolis-St. Paul hospitals. A sample of the records was abstracted (50% of 1995 records; 38% of 2000 records). A total of 2,257 patients in 1995 and 1,825 patients in 2000 were determined to have had a CHF-related hospitalization. Each patient was followed for one year to ascertain vital status. The risk profile of the 2000 patient cohort was somewhat worse than that of the 1995 cohort in both sex groups, but the distributions of age and left ventricular ejection fraction were similar. Within one year of admission in 2000, 28% of male patients and 27% of female patients have died, compared to 36% and 27% of their counterparts in 1995, respectively. In various Cox regression models the average year effect (2000 vs. 1995) was around 0.75 for men and 0.95 to 1.00 for women. The use of angiotensin converting-enzyme inhibitors and beta-blockers was associated with substantially lower hazard of death during the subsequent year. Survival of men who were hospitalized for CHF has improved during the second half of the 1990s. The trend in women was very weak, compatible with little to no change. Documented benefits of angiotensin converting-enzyme inhibitors and beta-blockers were evident in these observational data in both men and women.